Alerts will be sent to your verified email
Verify Email
AUROPHARMA
|
Aurobindo Pharma
|
Alkem Laboratories
|
Glaxosmithkline Phar
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in USA
|
861.0 . | 185.0 . | n/a |
|
Number of ANDA's Approved By USFDA
|
719.0 . | 158.0 . | n/a |
|
US DMF Filings
|
309.0 . | n/a | n/a |
|
Europe DMF Filings
|
2096.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
5.05 % | 5.0 % | 0.07 % |
|
Financials
|
|||
|
5 yr Average ROE
|
13.97 % | 17.42 % | 40.73 % |
|
5yr average Equity Multiplier
|
1.51 | 1.42 | 1.9 |
|
5yr Average Asset Turnover Ratio
|
0.71 | 0.89 | 0.94 |
|
5yr Avg Net Profit Margin
|
12.77 % | 13.9 % | 24.91 % |
|
Price to Book
|
2.02 | 4.93 | 29.4 |
|
P/E
|
18.91 | 27.26 | 61.85 |
|
5yr Avg Cash Conversion Cycle
|
-49.62 Days | -31.98 Days | -107.65 Days |
|
Inventory Days
|
59.48 Days | 55.32 Days | 52.59 Days |
|
Days Receivable
|
28.34 Days | 41.28 Days | 22.78 Days |
|
Days Payable
|
115.71 Days | 114.28 Days | 144.46 Days |
|
5yr Average Interest Coverage Ratio
|
43.78 | 24.2 | 479.64 |
|
5yr Avg ROCE
|
16.69 % | 22.93 % | 44.44 % |
|
5yr Avg Operating Profit Margin
|
19.28 % | 18.1 % | 25.23 % |
|
5 yr average Debt to Equity
|
0.21 | 0.21 | 0.0 |
|
5yr CAGR Net Profit
|
2.21 % | 9.76 % | 20.96 % |
|
5yr Average Return on Assets
|
9.18 % | 12.26 % | 21.84 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
51.82 % | 55.13 % | 75.0 % |
|
Share Pledged by Promoters
|
16.92 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.01 % | -2.0 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
8.12 % | 7.45 % | 1.0 % |
|
Aurobindo Pharma
|
Alkem Laboratories
|
Glaxosmithkline Phar
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|